Article Text

Download PDFPDF
Advances in targeted therapies XI
  1. F C Breedveld,
  2. J R Kalden,
  3. J S Smolen
  1. Correspondence to Professor F C Breedveld, LUMC, PO Box Leiden, Leiden 2300 RC, The Netherlands; f.c.breedveld{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The papers brought together in this supplement of the Annals of the Rheumatic Diseases constitute summaries of presentations at the XIth International Symposium on Advances in Targeted Therapies, which was held from 22 to 26 April 2009. These presentations represent the state of the art on the biology of mechanisms of action and pathophysiology of tumour necrosis factor (TNF) as well as other important mediators of inflammation. Current knowledge on the means and consequences of blocking TNF or other molecules or cellular mechanisms is also presented.

We are grateful to Drs Crofford, Feldmann, Furst, Klareskog, Lipsky, …

View Full Text


  • Competing interests None.

  • Provenance and Peer review Not commissioned; externally peer reviewed.

  • i The conference was organised under the sole responsibility of the departments of the Universities of Erlangen, Leiden and Vienna in collaboration with an Advisory Board consisting of the above-mentioned colleagues from departments of rheumatology of several US and European Universities. The following companies provided unrestricted educational grants for the organisation of this conference: Abbott, Amgen, Bristol-Myers Squibb, Merck, Roche, UCB and Wyeth. The pharmaceutical industry had no part in the decisions about the specific programme and, with the exception of a few observers, participants were selected and solely invited by the Organising Committee. Several members of the Advisory Board and the members of the Organising Committee have obtained experience in the use of biological compounds in the course of their participation in clinical studies on these agents (for which the costs were defrayed by industry).